Results 71 to 80 of about 7,229 (203)

Comparable real‐world effectiveness between switches to cabotegravir + rilpivirine long‐acting or modern daily oral regimens in the United States: an OPERA cohort study

Journal of the International AIDS Society
Introduction Cabotegravir + rilpivirine long‐acting (CAB+RPV LA) injectable was approved in the United States in 2021 for HIV‐1 treatment in virologically suppressed (viral load [VL]
Ricky K. Hsu, Michael G. Sension, Jennifer S. Fusco, Laurence Brunet, Quateka Cochran, Brooke Levis, Gayathri Sridhar, Vani Vannappagari, Jean Van Wyk, Michael B. Wohlfeiler, Gregory P. Fusco   +10 more
doaj   +1 more source

Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients

BMC Infectious Diseases, 2017
Background Switch strategies based on rilpivirine/tenofovir/emtricitabine or on an integrase inhibitor (InSTI) plus tenofovir/emtricitabine have never been compared in randomized clinical trials.
Nicola Gianotti, Andrea Poli, Silvia Nozza, Laura Galli, Nadia Galizzi, Marco Ripa, Marco Merli, Alessia Carbone, Vincenzo Spagnuolo, Adriano Lazzarin, Antonella Castagna   +10 more
doaj   +1 more source

Advancing Antiviral Design: Integrating Natural Products, Computation and Targeted Delivery

Chemical Biology &Drug Design, Volume 108, Issue 1, July 2026.
A stepwise translational framework linking natural‐product discovery, computational prioritisation, experimental validation, lead optimisation and targeted delivery is proposed to advance antiviral design. ABSTRACT The COVID‐19 pandemic highlighted the role of rapid viral mutation and global connectivity in accelerating viral emergence and spread ...
Adedayo Ayodeji Lanrewaju, Abimbola Motunrayo Folami, Saheed Sabiu, Feroz Mahomed Swalaha   +3 more
wiley   +1 more source

Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project

Infection and Drug Resistance, 2018
Paola Bagella,1 Giuseppe VL De Socio,2 Elena Ricci,3 Barbara Menzaghi,4 Canio Martinelli,5 Nicola Squillace,6 Paolo Maggi,7 Giancarlo Orofino,8 Leonardo Calza,9 Laura Carenzi,3 Benedetto Maurizio Celesia,10 Giovanni Penco,11 Antonio Di Biagio,12 Laura ...
Bagella P, De Socio GVL, Ricci E, Menzaghi B, Martinelli C, Squillace N, Maggi P, Orofino G, Calza L, Carenzi L, Celesia BM, Penco G, Di Biagio A, Valsecchi L, Vichi F, Colombo V, Parruti G, Dentone C, Falasca K, Bonfanti P, Madeddu G   +20 more
doaj  

Efficacy of dolutegravir/lamivudine in adults with HIV‐1 and isolated reactive hepatitis B core antibody: Insights from Phase 3/3b study results

HIV Medicine, Volume 27, Issue 7, Page 1189-1195, July 2026.
Abstract Objectives As two‐drug HIV‐1 antiretroviral therapy (ART) regimens become standard, data gaps remain concerning their safety and efficacy among people with isolated reactive hepatitis B core antibodies (anti‐HBc). Here, we assessed the safety and efficacy of dolutegravir/lamivudine (DTG/3TC) versus three‐ or four‐drug regimens (3DRs/4DRs ...
D. Fox, J. Slim, E. T. Overton, A. Doblado‐Maldonado, P. Jeffery, R. A. Grove, S. D. Advani, R. Borsi, C. M. Parry, M. Underwood, B. Jones   +10 more
wiley   +1 more source

Triple-combination rilpivirine, emtricitabine, and tenofovir (Complera™/Eviplera™) in the treatment of HIV infection

, 2013
Claudia Bernardini, Franco MaggioloDivision of Infectious Diseases and Unit of Antiviral Therapy, AO Papa Giovanni XXIII, Bergamo, ItalyAbstract: The combination rilpivirine (RPV)/emtricitabine (FTC)/tenofovir (TDF) is a once-daily, single-tablet regimen
Bernardini C, Maggiolo F
core  

Stability indicating RP-UPLC determination of three antiviral agents: emtricitabine, tenofovir, and rilpivirine in combined pharmaceutical dosage form

Future Journal of Pharmaceutical Sciences
Background The concurrent measurement of emtricitabine, tenofovir, and rilpivirine was achieved using UPLC, employing Analytical Quality by Design (AQbD) principles, which encompass response surface methodology (RSM) and Box–Behnken design (BBD).
Vinutha Kommineni, Spoorthi Pohar, N. Sri Lakshmi, N. Swarna Latha   +3 more
doaj   +1 more source

Improved Central Nervous System Symptoms in People with HIV without Objective Neuropsychiatric Complaints Switching from Efavirenz to Rilpivirine Containing cART

Brain Sciences, 2019
Objective: Occult central nervous system (CNS) symptoms not recognized by people living with HIV (PLWH) receiving efavirenz or their clinicians could occur and impact people’s quality of life.
Jaime H. Vera, Margherita Bracchi, Jasmini Alagaratnam, Julianne Lwanga, Julie Fox, Alan Winston, Marta Boffito, Mark Nelson   +7 more
doaj   +1 more source

Do people with HIV really have the choice between oral and injectable ART? Evidence from a multicentric survey in the Swiss HIV cohort study

HIV Medicine, Volume 27, Issue 7, Page 1156-1167, July 2026.
Abstract Introduction Injectable long‐acting antiretroviral therapy (iLA‐ART) offers a valuable alternative to oral ART (oART). While the efficacy of these treatment strategies is similar, adequate information on their specific characteristics is essential to enable people with HIV (PWH) to decide which option best suits their values and preferences ...
Yonas Martin, Bernard Surial, Martin Müller, Lukas Baumann, David Jackson‐Perry, David Haerry, Marie Ballif, Charles Béguelin, Miriam Bürgi, Aline Munting, Matthias Cavassini, Dominique Braun, Andri Rauch, Reto Auer, Gilles Wandeler, the Swiss HIV Cohort Study   +15 more
wiley   +1 more source

Where rilpivirine meets with tenofovir, the start of a new anti-HIV drug combination era

, 2012
The triple-drug once-daily combination pill containing tenofovir, emtricitabine and rilpivirine for HIV treatment was launched in 2011, both in the USA (Complera) and the E.U. (Eviplera).
Erik De Clercq, De Clercq, Erik
core   +1 more source